2015 Symposium

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2015 Symposium: Save the Date!

Our 11th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium will be taking place on Thursday February 19, 2015.

Featured speakers will include:

Keynote Speaker
Elaine Mardis, PhD
The Genome Institute
Washington University School of Medicine

Keynote Speaker
Brian Druker, MD
OHSU Knight Cancer Institute

Ricardo Attar, PhD
Senior Director, Heme Stronghold Discovery Lead, Oncology Discovery
Janssen Research & Development

Rafael Bejar, MD, PhD
Moores Cancer Center

David Brenner, MD
UCSD School of Medicine

David Cheresh, PhD
Moores Cancer Center

Ezra Cohen, MD
Moores Cancer Center

Gregory Daniels, MD
Moores Cancer Center

Napoleone Ferrara, MD
Moores Cancer Center

Janet Freeman-Daily
Patient Advocacy

Trey Ideker, PhD
UC San Diego

Catriona Jamieson, MD, PhD
Moores Cancer Center

Pradeep Khosla, PhD
UC San Diego

D. Lynn Kirkpatrick, PhD
President and Chief Executive Officer
PHusis Therapeutics Inc.

Bob Klein
President, Founder, and CEO
Klein Financial Corporation

Razelle Kurzrock, MD
Moores Cancer Center

Scott Lippman, MD
Moores Cancer Center

C. Randall Mills, PhD
President and Chief Executive Officer
California Institute for Regenerative Medicine

Hans-Joachim Mueller, PhD
Expert Scientist, Discovery Oncology, Roche Pharma Research and Early Development, Innovation Center Penzberg
Roche Diagnostics GmbH

Margo Roberts, PhD
Chief Scientific Officer
Kite Pharma

Charles Theuer
Chief Executive Officer
TRACON Pharmaceuticals

Judith Varner, PhD
Moores Cancer Center

If you have any questions, including registration, or are interested in sponsorship, please contact Leisa at lsutton@ucsd.edu. Thank you!

Symposium Press

San Diego ABC 10 News reporter Michael Chen interviewed San Diego resident Heather Clark, a patient of Moores Cancer Center, along with Ida Deichaite, Director of Industry Relations & Symposium Organizer, in a video report about the I-SPY Clinical Trial and Symposium. The I-SPY Clinical Trial is lead by 2014 Symposium Keynote Speaker and Principle Investigator Laura Esserman, MD, MBA. For the video, see here.

“When you go to an international cancer symposium with 30,000 people, it’s hard to get to the real champion of a project and get their individualized attention. The Moores Cancer Center Translational Oncology Symposium is much more intimate. Industry and academia are on equal footing and there are plenty of opportunities for informal discussions when a lot of synergies develop and collaborations begin or grow.”

- Catriona Jamieson, Ph.D., M.D.,
Director of Stem Cell Research at Moores Cancer Center

The MCC Translational Oncology Symposium is designed as an international forum to foster introductions, stimulate productive conversations among people of complementary interests and galvanize collaborations that will have a profound impact on patient health. It’s a melding of minds in the field of cancer research. Represented will be many of the different skill sets needed to bring a new drug to market – from the lab, through the commercialization process to the patient’s bedside.

Hear from global thought leaders in some of the most promising frontiers of research and treatment, including immunotherapy, antibodies and personalized medicine. Meet top academic researchers, renowned clinicians, and top business development professionals and scientists from the world’s leading pharmaceutical companies and innovative biotechnology companies working in oncology.

In a global environment of budget cuts, including investment in scientific research, industry/academia collaborations are crucial to leverage resources and expertise. In its first nine years, the MCC Translational Oncology Symposium has shown great success in forging collaborations that are speeding drug development times and saving lives:

  • Collaboration between Pfizer and MCC led to a multisite international clinical trial of a sonic hedgehog inhibitor. One patient who was told she had just months to live is alive three years later and has undergone a bone marrow transplant after participating in the trial.
  • Collaboration between San Diego-based TargeGen, MCC and Standord University, which sped the development of a JAK2 inhibitor and led to the acquisition of TargeGen.

Symposium Organizers and Chairs

Symposium Organizers:

Scott Lippman, MD
UCSD Moores Cancer Center

Symposium Chair:

David Cheresh, PhD
Associate Director for Innovation and Industry Alliances, Distinguished Professor of Pathology
UCSD Moores Cancer Center

Ida Deichaite, PhD
Director, Industry Relations
UCSD Moores Cancer Center

Symposium Co-Chair:

Catriona Jamieson, MD, PhD
Director, Stem Cell Research Program, Associate Professor of Medicine
UCSD Moores Cancer Center

We Thank Our Past Supporters: